Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same author

Di-Silyl Rhodium(III) and Iridium(III) Complexes as Catalysts in Carbene Insertion Reactions into Hydrosilanes.

Organometallics·2026
Same author

Designing interventions guided by digital phenotype and pharmacogenetics in Spain for suicidal behaviour based on retrospective data: the multicentre SMARTomicS study protocol.

BMJ open·2026
Same author

Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.

Drug delivery·2026
Same author

Screening-confirmation approach for urinary alpelisib by silver-nanorod enabled portable SERS platform and LC-MS validation.

Analytical and bioanalytical chemistry·2026
Same author

Fine-Tuning the SMM Properties of a Bis(ZnDy)-Based Compound by Rationally Reducing/Increasing the Electron Density in the Equatorial Plane Perpendicular to the O<sub>phenoxido</sub>-Dy-O<sub>phenoxido-bridges</sub> Direction.

Inorganic chemistry·2026
Same journal

Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases.

Journal of medicinal chemistry·2026
Same journal

Recent Advances in Targeting RNA Splicing Factors with Small Molecules.

Journal of medicinal chemistry·2026
Same journal

Structure-Guided Optimization of α-Conotoxins Yields Potent and Selective Inhibitors of the Human α6β4 nAChR for Nicotine Addiction.

Journal of medicinal chemistry·2026
Same journal

Antibody-Assisted Protection from Paraoxon and Nerve Agent Model Compounds.

Journal of medicinal chemistry·2026
Same journal

Photocage Prodrug Coupled with Injectable Hydrogel for Self-Amplified Photochemotherapy.

Journal of medicinal chemistry·2026
Same journal

GPX4-Targeting Phenolato Zr<sup>IV</sup> Complexes Induce Ferroptosis and Lysosome-Dependent Cell Death for Immunotherapy of Chemoresistant Cancer.

Journal of medicinal chemistry·2026
See all related articles
  1. Home
  3. Exploring Gallium(iii) Complexes As Emerging Therapeutic Candidates For Breast Cancer.
  1. Home
  3. Exploring Gallium(iii) Complexes As Emerging Therapeutic Candidates For Breast Cancer.

Related Experiment Video

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

10.6K

Exploring Gallium(III) Complexes as Emerging Therapeutic Candidates for Breast Cancer.

Alberto Moreno-Fernández1, Elena Domínguez-Jurado2, Marc Martínez de Sarasa Buchaca1

  • 1Universidad de Castilla-La Mancha, Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Ciencias y Tecnologías Químicas, Instituto Regional de Investigación Científica Aplicada-IRICA, 13071 Ciudad Real, Spain.

Journal of Medicinal Chemistry
|April 6, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

New gallium(III) heteroscorpionate salts show high stability and potent anticancer activity against breast cancer cell lines. The lead compound demonstrated significant tumor growth inhibition in vivo with minimal toxicity.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

12.2K

Related Experiment Videos

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue
11:22

Investigations on the GaIII Complex of EOB-DTPA and Its 68Ga Radiolabeled Analogue

Published on: August 17, 2016

10.6K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.3K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

12.2K

Area of Science:

  • Medicinal Chemistry
  • Inorganic Chemistry
  • Cancer Biology

Background:

  • Platinum-based chemotherapeutics face limitations due to severe side effects and acquired resistance.
  • Gallium compounds offer potential as metallodrugs by mimicking iron(III) and interfering with cellular processes.
  • Previous gallium compounds suffered from poor stability and moderate efficacy, hindering their clinical translation.

Purpose of the Study:

  • To develop novel gallium(III) complexes with improved stability and enhanced anticancer cytotoxicity.
  • To investigate the structure-activity relationship of heteroscorpionate ligands in gallium(III) complexes.
  • To evaluate the in vitro and in vivo efficacy and toxicity of promising gallium(III) candidates.

Main Methods:

  • Synthesis and characterization of a new family of heteroscorpionate gallium(III) salts ([Ga(κ3-NNO)2][GaCl4], Ga1-Ga6).
  • Structural elucidation using NMR spectroscopy and single-crystal X-ray diffraction.
  • In vitro cytotoxicity assays against breast cancer cell lines and in vivo studies in zebrafish xenografts and mice.

    • Main Results:

    • The synthesized gallium(III) complexes exhibited excellent air and moisture stability.
    • Lipophilicity and solubility were tunable via ligand electronics, with dimethylamino-substituted complexes (Ga3, Ga6) showing nanomolar cytotoxicity.
    • The lead compound, Ga6, demonstrated high hydrolytic stability, selective tumor uptake, and significant tumor growth inhibition in zebrafish xenografts with no observable systemic toxicity in mice.

    Conclusions:

    • Heteroscorpionate gallium(III) complexes represent a promising new class of metallodrugs with potent anticancer activity.
    • The developed compounds overcome the limitations of previous gallium agents, offering improved stability and efficacy.
    • The lead compound Ga6 warrants further investigation as a potential therapeutic agent for breast cancer treatment.